Global Action Plan on HIVDR 2018 Progress Report

Slides:



Advertisements
Similar presentations
New Challenges in M&E Lets go. Scaling Up Monitoring & Evaluation Strategic Information PROGRAM GUIDANCE RESULT NEEDS OPPORTUNITIES Resources New directions.
Advertisements

Track C on prevention issues Recognised Priority technical areas are ITNs, malaria in pregnancy, vector control, including use of DDT epidemics and complex.
Why Mutual Accountability? Aid effectiveness requires country ownership, including in donor coordination Contradictions: (a) power imbalance, (b) broken.
Preventing HIV Drug Resistance with Programmatic Action Michael R. Jordan MD MPH.
A Global Framework for Public Health Functions Taskforce for World Federation of Public Health Associations Draft for discussion 15 th May 2014.
Comprehensive M&E Systems
1 HIV Drug Resistance Training Module 9: A Systems Approach to Laboratory Quality.
At What Cost? U.S. Leadership in Global Health in an Era of Austerity Dr. J. Stephen Morrison Senior Vice President; Director, Global Health Policy Center.
Presentation Title Presenter(s) Centers for Disease Control and Prevention AIDS Turning the Tide Together.
Partnerships in Promoting Innovation and Managing Risk Scientific and Financial Innovation in AIDS Vaccines International AIDS Vaccine Initiative Labeeb.
Elliot Raizes, MD HIV Care and Treatment Branch AIDS 2012: WHO Satellite Symposium HIV Drug Resistance Surveillance and Control: A Global Concern July.
Conclusions of the meeting and closing remarks. Chronology 1981Hepatitis B vaccine becomes available 1991World Health Assembly resolution call for the.
Dr. Mwendwa Eunice Mwenesi, Tanzania Ministry of Health and Social Welfare, Presentation to the mHealth Working Group, Washington DC, December 1 st, 2011.
The WHO HIV Drug Resistance Strategy Presented by Dr. Don Sutherland Prepared by: Dr. Don Sutherland Dr Silvia Bertagnolio Dr Diane Bennett HIV Drug Resistance.
Overcoming HIV/AIDS Epidemic in Ukraine National programme supported by GFATM.
Pharmacovigilance in HIV/AIDS Public Health Programmes: Luxury or Priority? November 2009, dar Es Salaam.
HIV TESTING AND EXPANSION OF ART FOR TB PATIENTS, BOTTLE NECKS CHALLENGES AND ENABLERS FOR SCALE UP IN KENYA DR. JOSEPH SITIENEI, OGW NTP MANAGER - KENYA.
ARV Treatment Scale Up: Progress in Ukraine Andriy Klepikov Executive Director, International HIV/AIDS Alliance in Ukraine ARV Treatment Scale Up: Progress.
2007 Pan American Health Organization 2004 Pan American Health Organization Malaria in the Americas: Progress, Challenges, Strategies and Main Activities.
Meeting the Global Challenge ~ International workshop on antiviral drug resistance.
Country name Name of the Speaker Title, Organization.
HIV Drug Resistance Surveillance Satellite Session: HIV Drug Resistance Surveillance and Control: a Global Concern Silvia Bertagnolio, MD WHO,
#AIDS2016 ASSESSMENT OF THE WORLD HEALTH ORGANIZATION EARLY WARNING INDICATORS OF HIV DRUG RESISTANCE IN NAMIBIA FOR PUBLIC HEALTH ACTION,
Launched March at UN Statistical Commission in side event.
WHO Global Health Sector Strategies HIV; Viral Hepatitis; Sexually Transmitted Infections Common structure Universal Health Coverage SDGs Cascade.
Outline The Global Fund Strategy emphasizes the Key Populations
New WHO Guidelines on Person centred monitoring
Demanding a high impact HIV response: civil society advocacy and the President’s Emergency Plan for Aids Relief (PEPFAR) Dorothy Namutamba International.
Contents Global impact 2.Service cascade 3. Policies and WHO support.
Investing in the Breastfeeding Movement in India
Zambia - Vision Long term vision Focus for
Differentiated Service Delivery: Innovating for Impact
WHO’s prioritised research agenda for the prevention and control of NCDs prioritises
Background Consensus Managing for Development Results
Is E2 sufficient to ensure sustainability?
USAID SHIFT YEAR1 Technical Strategies and Priority TA
Gender statistics in Information and Communication Technology for Women’s Empowerment and Gender Equality Dorothy Okello, Annual.
GENDER STATISTICS IN INFORMATION AND COMMUNICATION
Setting the Scene: Global Plan Progress,
Achieving the SPF Guarantees: Recommendations from group discussions
Access Equity in Prisons in Africa A CALL FOR ACTION
PARIS21 Workshop Strategic Statistical Planning GDDS and NSDS links July 27-28, 2005 Accra, Ghana Oliver J.M Chinganya, Regional Advisor, GDDS-Anglophone.
Stop TB Partnership Secretariat (TBP)
Monitoring the implementation of the TB Action Plan for the WHO European Region, 2016–2020 EU/EEA situation in 2016 ECDC Tuberculosis Programme European.
Call topic identification for 2019 call
Funding gap: $ 31 bn.
Session 4: SDG follow-up and review mechanisms
Antiretroviral therapy coverage in sub-Saharan Africa,
Antibiotic Resistance: Strategic Solutions
NASTAD Update CSTE Annual Conference
World Tuberculosis Day 2016
Aid for Development Effectiveness -Managing for Development Results-
Serge Masyn Director, Johnson & Johnson Global Public Health
Update on HIV and TB situation in SEAR Dr Mukta Sharma RA HIV TB HEP WHO SEARO Global Fund , South-East Asia Constituency Meeting, April 2018,
GFOI Plenary Breakout Groups: GFOI priorities
TB Strategy & Health Systems (TBS) TB Monitoring & Evaluation (TME)
Key components of an NSDS
The ProTEST Projects:Achievements so far
Issues on the current information system
Contents Global impact 2.Service cascade 3. Policies and WHO support.
A Time of Commitments and Actions to accelerate action to End TB
Institute for State Effectiveness (c) 2009
Comprehensive M&E Systems
HIV Among Gay and Bisexual Men and Other Men Who Have Sex With Men
Silvia Bertagnolio, MD HIV Department World Health Organization
Target-Setting, Impact and Resource Needs
Institutional arrangements
Start Free, Stay Free, AIDS Free
Update on global progress in ART
PARIS21 Secretariat paris21 board meeting – paris 3 april 2019
Presentation transcript:

Global Action Plan on HIVDR 2018 Progress Report In 2017, WHO jointly with partners developed the global action plan to address the rising levels of drug resistance. This year, we assessed the progress in implementation and areas where additional focus is needed

Global Action Plan on HIV Drug Resistance (HIVDR) Summary of progress (2018) ↓ Suboptimal progress in HIVDR prevention ↓ Slow response to high levels of pretreatment HIVDR Prevention & Response Monitoring & Surveillance Research & Innovation Laboratory Capacity Governance & Enabling Mechanisms ↑ Increased uptake of HIVDR surveys ↓ Need for better monitoring of program quality ↑ Positive progress in addressing research gaps on HIVDR ↓Suboptimal viral load testing coverage ↑ Improved capacity for DR testing for surveillance ↑ Increased country ownership ↑ Increased support by donors ↑ Initial involvements of community groups